EUVIMED · CrossrefZeitschrift
CPT: Pharmacometrics & Systems Pharmacology
ISSN 2163-8306 · Wiley
Neueste Artikel
Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant
Drug–Drug Interactions of Cenobamate With Medications: Dose‐Dependent Induction/Inhibition and Clinical Implications
Assessment of Allometric Scaling Methods for the Prediction of Human Pharmacokinetic of LNA ‐i‐ miR ‐221
Reframing QSP : AI ‐Driven Multi‐Modal Data as a New Measurement Layer
Comparing the Effectiveness of a Longitudinal Model With Logistic Regression for Binary Endpoints to Support Better Clinical Decision Making
Model‐Informed First‐In‐Human Dose Selection for AZD2796 , a High‐Affinity Anti‐ LILRB2 Antibody
Application of Physiologically Based Pharmacokinetic Modeling to Optimize Assessment of Age‐Related Fluoxetine Accumulation in the Elderly
Pharmacokinetics, Pharmacodynamics, Efficacy and Drug Resistance Selection of Injectable Long‐Acting Lenacapavir Pre‐Exposure Prophylaxis ( PrEP ) Against HIV
Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development
Translational Modeling of Gut Microbiome‐Mediated Drug Metabolism: A Case Example of Sulfasalazine
Quantitative Systems Pharmacology Modeling Amid the Rise of Agentic AI
What Is a Digital Twin in QSP , and Are We Doing It Right?
Impact of Event‐Related Treatment Modifications in Exposure‐Response Analyses of Repeated Time‐to‐Event Data
A Model‐Based Meta‐Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials
Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR ‐ SB Utilizing Semi‐Mechanistic Model
Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA ‐4359 for Use in First‐In‐Human Trials
Tutorial on Causal Mediation Analysis for Pharmacometricians
Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting
Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model
Generating Control Groups for Organ Impairment Studies: A Case‐Study Comparing Statistical and Population Pharmacokinetic‐Based Matching Approaches
Neural Controlled Differential Equation and Its Application in Pharmacokinetics and Pharmacodynamics
Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices
A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe
A Unified Whole Lung PBK Model for Inhalational Uptake of Gases and Aerosols in Men
Evaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs
AI for NONMEM Coding in Pharmacometrics Research and Education: Shortcut or Pitfall?
A model‐informed clinical trial simulation tool with a graphical user interface for Duchenne muscular dystrophy
A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies
Clinical modeling of motor function to predict treatment efficacy and enable in silico treatment comparisons in infantile‐onset Pompe disease
Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach
EUVIMED